NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer

Inclusion Criteria: * Females age 18 years or older. * The ability to provide written informed consent prior to study specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time. * Histologically confirmed infiltrating (invasive) breast cancer by core needle biopsy, with no evidence of metastatic disease except to the ipsilateral axillary lymph nodes. * Clinical stage IIB - IIIC (T2-4, N0 or N1, M0 or - any T, N1-3, M0) breast cancer. The primary tumor must be greater than or equal to 2 cm (T2-4) or with pathologically proven axillary nodal involvement (N1-3). * Patients with inflammatory breast cancer (T4) are permitted into the study. * Clinically palpable tumor that meets the criteria of RECIST for palpable measurable disease. The primary tumor must be greater than or equal to 2 cm (T2-4) or with pathologically proven axillary nodal involvement (N1-3). Bilateral synchronic breast cancers are allowed but one of the primary tumors should be selected as the target tumor. * Primary tumor may be estrogen or progesterone receptor negative or positive, and human epidermal growth factor receptor 2 (HER-2/neu) negative as determined by either Fluorescent In Situ Hybridization (FISH) or 0-2+ staining by immunohistochemistry (IHC) (Hercept™). * Normal cardiac ejection fraction (EF ≥ 50%) as determined by screening multigated acquisition scan (MUGA) or echocardiogram. * No prior history of myocardial infarction, congestive heart failure, symptomatic coronary artery disease, or cardiac arrhythmias. * Patients must be ambulatory with Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1. * The patient or her caregiver must be able to self administer daily subcutaneous injections. * Life expectancy greater than 6 months. Exclusion Criteria: * Prior therapy of any modality for the treatment of breast cancer * Any prior therapy with an anthracycline or a taxane for any other indication * HER-2 positive breast cancer defined as either gene amplification by Fluorescent In Situ Hybridization (FISH) or 3+ staining by IHC (Hercept™). * Women who have a positive pregnancy test, no pregnancy test available, who are pregnant or who are lactating. * Women of childbearing potential must agree to use a reliable and appropriate contraceptive method, which could include a double barrier method (condom plus diaphragm), an intrauterine device or oral contraceptives. Women with ER or PR positive breast cancer, should not, however, use oral contraceptives as a method of contraception. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential. * Women with breast cancer that do not have palpable breast tumors at screening. * History of another malignancy within the last 5 years except curatively treated basal cell carcinoma of the skin or cervical intraepithelial neoplasia. * Clinically significant (i.e. active) cardiac disease (NYHA Grade II or greater congestive heart failure, symptomatic coronary artery disease, unstable angina, and cardiac arrhythmia not well-controlled with medication), myocardial infarction within the last 6 months prior to study start, or screening ejection fraction of \< 50%. * Any of the following abnormal laboratory values: * Absolute neutrophil count \< 1.5 x 109/L * Platelet count \< 100 x 109/L * Serum bilirubin \> 1.5 x upper limit of normal (ULN) * Serum alanine transaminase (ALT), aspartate transaminase (AST) \> 2.5 x ULN * Serum creatinine \> 2.0 mg/dL or 177mmol/L or calculated creatinine clearance by the method of Cockcroft and Gault \< 50mL/min). * Any severe or poorly controlled systemic disease (e.g., hypertension; clinically significant cardiovascular, pulmonary, or metabolic disease, disorders of wound-healing, ulcer or bone fracture). * Patients who have received any investigational treatment within 4 weeks of study start. * Known infection with HIV, Hepatitis B virus (HBV), or Hepatitis C virus (HCV). * Known hypersensitivity to any of the components of NOV-002 or to any of the study drugs. * Patients assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.